Zortix matched this thesis to Biotech ETFs as one way for retail investors to get exposure. Not a recommendation.
Biotech innovation tailwind amid funding drought
The bull case for biotechnology was argued: an explosion of new therapeutic modalities (mRNA, cell therapies, etc.) has made drug development less risky, creating a powerful innovation tailwind, even as the sector faces a severe funding shortage.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.